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Abstract
Background: Little is known about the incidence of virological failure among Human Immunodeficiency virus (HIV)
infected adults after Uganda transitioned from Zidovidine/Lamivudine/ Nevirapine (AZT/3TC/NVP) to Tenofovir/
Lamivudine/Efavirenze (TDF/3 T/EFV) as a first-line anti-retroviral therapy (ART) in 2013. This was the first study in
Uganda to investigate the incidence and predictors of virological failure among HIV-positive adults in Northwestern
Uganda.
Method: A retrospective cohort of 383 HIV-positive adults at Arua Teaching and Regional Referral Hospital HIV
Clinic with at least six months of ART duration and five consecutive good adherence levels was used. Socio-
demographic and clinical variables were analyzed with STATA version 12 at 5 % significance level. The Chi-squared,
Fisher’s exact and Student’s t-tests were used for bivariate analysis. Cox Proportional Hazard Regression analysis was
used for univariable and multivariate analysis, Kaplan-Meier for comparison of survival probability and the log-rank
for testing survivorship probability. Hazard ratios (HR), 95 % confidence intervals (CI) and probability values were
stated.
Results: The average age of the cohort was 34.0 ± 11 years (Median: 32 years, Interquartile range (IQR): 25–31
years). 28 (7.3 %; 95 % Confidence Interval [CI]: 4.9-10.6) incident cases of virological failures and an incidence rate
of 58 per 1000 person-years over risk time of 483 years was recorded. One-kilogram baseline body weight
difference (41-kg and above) at ART initiation (Adjusted Hazard Ratio [aHR] = 0.86, 95 % CI:0.76-0.96, P = 0.008), one-
CD4 cell increase (35 cells/ul and above) after ART initiation (aHR = 0.99, 95 % CI: 0.98-0.99, P < 0.001) and HIV-
serostatus disclosure (aHR = 0.15, 95 % CI: 0.06-033, P < 0.001) reduced the hazard of virological failure.
Conclusion: Virological failure is common among HIV-positive adults in Northwestern Uganda. It reduced with
extra baseline weight, rising CD4 cell counts and HIV-serostatus disclosure.
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Background
Anti-retroviral therapy (ART) inhibits the replication
of Human Immunodeficiency Virus (HIV) reflected by
undetectable plasma HIV concentration (lower than
50 copies /ml) for as long as possible. Since the arrival
of ART, many countries adopted ART regimes based
on efficacy, durability, tolerability, ease of use, avail-
ability, continuity of supply and potential for future
use. In 2011, Ministry of Health-Uganda ART guide-
lines recommended the use of Tenofovir-Lamivudine
(TDF/3TC) with either Nevirapine (NVP) or Efavir-
enze (EFV) as the preferred first-line option and
Zidovudine-Lamivudine (AZT/3TC) with NVP or EFV
as a first-line alternative [1].
In June 2013, the 2011 ART guideline was revised to
incorporate the World Health Organization (WHO)
ART recommendations [2]. The revisions included the
substitution of AZT for TDF in adult regimen and,
AZT for ABC in children less than 10 years old or
weighing less than 35 kg. This was critical because
HIV resistance to TDF or ABC does not confer resist-
ance to AZT and 3TCbut rather, preserve them for
second-line ART use. Secondly, it increase the suscep-
tibility of HIV resistant strains to protease inhibitors
(PIs) and AZT/3TC [1, 3]. With this revisions, the pre-
ferred first line ART became TDF/3TC/EFV. TDF/
3TC/EFV was preferred because of the relatively low
toxicity profile compared to other ART combinations,
potential for improved adherence due to low pill
burden (once daily dosing), and low renal toxicity pro-
file of 3 %, safe use in pregnancy and with anti-
tuberculosis medications. Consequently, the first and
second-line alternatives became AZT/3TC/NVP and
AZT/3TC/EFV respectively [2].
However, ART is limited by drug interactions, drug re-
sistances that reduce its potency, incidences of adverse
reactions, need to ensure nearly perfect adherence of at
least 95 %, and treatment failures [1]. Resultantly, viral
load testing is nowadays preferred over clinical and im-
munological monitoring to determine HIV replication
and to evaluate ART effect on HIV progression and ag-
gressiveness. In addition, viral load testing is a good
marker in monitoring a successful ART program par-
ticularly the effectiveness [1].
The change in ART policy led to enrollment of substan-
tial number of HIV-positive adults on TDF/3TC/EFV.
However, even with the known several challenges of ART,
presently, there is paucity of information on the incidence
and predictors of virological failure following the change in
ART policy and subsequent implementation. This study
therefore assessed the incidence, socio-demographic and
clinical factors associated with virological failure among
HIV-positive adults at Arua Teaching and Regional Referral
Hospital HIV Clinic, North-Western Uganda.
Method
This was a retrospective cohort study of HIV-positive
adults enrolled on ART between June 2013 and December
2015. We analyzed data from 383 HIV-positive adults with
five consecutive records of good ART adherence and ART
use for at least six months (Fig. 1). Descriptive statistics of
frequencies and percentages were computed and tabu-
lated. In particular, numerical data was summarized into
mean, standard deviation (SD), median and interquartile
range (IQR).
The outcome variable was a composite measure of
time to virological failure. Time was take as the duration
from the date of ART initiation to the date of viral load
assessment. Virological failure was defined as viral load
greater than 5,000 copies/ml on two consecutive dry
blood spot viral load measurements at least six months
apart with adherence support; confirmed by plasma viral
load of at least 1,000 copies/ml [2].
The independent variables were socio-demographic
factors (sex, age, tribe, residence, marital status, occupa-
tion, education and religion) and clinical factors (CD4
before and after ART, body weight before and after ART,
WHO clinical staging before and after ART, HIV seros-
tatus and, functional status before and after ART). The
incidence rate of virological failure was computed as the
number of virological failures per 1000 person-years of
observation.
Associations between the outcome variable and categor-
ical independent variables were analyzed by Chi-squared
test for larger cell counts (equals or more than five), or the
Fisher’s exact test for smaller cell counts (less than five).
Meanwhile, the Student’s t-test was used to analyze associa-
tions between numerical independent variables and out-
come variable. Chi-squared, Fisher’s exact and Student’s t-
test probability values (P-values) less than 0.2 together with
clinically relevant independent variable(s) were taken
Fig. 1 Study profile of HIV-positive adults at Arua Teaching and Re-
gional Referral Hospital, Northwestern Uganda
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significant for univariable Cox Proportional Hazard regres-
sion analysis. The results were stated in unadjusted hazard
ratios (uHR) with, 95 % confidence intervals (95 % CI) and
P-values.
P-values less than 5 % at univariable analysis were con-
sidered significant for multivariable Cox Proportional
Hazard regression analysis and, results stated in adjusted
hazard ratios (aHR), 95 % CI and P-values. Multivariable
analysis controlled confounders and effect modifiers
resulting into correct conclusions. The Kaplan-Meier
curve was used to compare survival probabilities for sig-
nificant variable(s) and differences in survivorship of
virological failure tested by log-rank test. All HIV posi-
tive adults had written informed consent at enrolment
into HIV care. The HIV clinic observe a written policy
on patient rights: privacy, confidentiality of information,
autonomy and respect among others. The Institutional
Review Board of Arua Teaching and Regional Referral
Hospital approved this study.
Results
General characteristics of respondents
651 HIV-positive persons were enrolled on ART during
the study period but 268 (41.2 %) were excluded. Of the
268, 226 (84.3 %) were on ART for less than six months
and 42 (15.7 %) had no viral load results (Fig. 1).
Of 383 respondents, 214 (55.9 %) were above 30 years of
age, 238 (62.1 %) were females, 294 (76.8 %) were rural resi-
dents (stay 15 km away from Arua town), 234 (61.1 %) were
married, 167 (43.6 %) were self-employed, 154 (40.2 %)
ended at secondary level of education, 203 (53.0 %) were
Catholics and 290 (75.7 %) were Lugbara ethnic tribe
(Table 1). The average age of participants was 34 ± 11 years
(Median: 32 years, IQR: 25–41 years). The mean baseline
weight was 58.42 ± 8.01 kg (Median: 56.0, IQR: 53–62.0)
but ranged from 41.0-87.5 kg. Similarly, the mean most re-
cent CD4 count was 378 ± 140 cells/uL (Median: 362, IQR:
286–453) with a range of 35–981 cells/uL.
Incidence of virological failure among HIV-positive adults
on first-line ART in Northwestern Uganda
The incidence rate of virological failure was 58 per 1000
person-years over risk-time of 483 years. The cumulative
number of virological failure was 28 (7.3 %; 95 % CI: 4.9-
10.6).
Univariable analysis of factors associated with virological
failure among HIV-positive adults on first-line ART in
Northwestern Uganda
Compared to males, female HIV-infected adults had
55 % reduction in the hazard rate of virological fail-
ure (Unadjusted hazard ratio (uHR) = 0.45, 95 % CI:
0.21-0.95, P = 0.035). HIV-positive adults in World
Health Organization (WHO) clinical stages III & IV
had 40.0 % lower hazard rate of virological failure
compared to those in WHO Clinical stages I & II
(uHR = 0.60, 95 % CI: 0.08-4.40, P = 0.612).
The incidence of virological failure was higher
among HIV-infected adults with baseline body weight
less or equals to 56 kg compared to those weighing
over 56 kg. A baseline body weight of over 56 kg was
associated with reduced hazard rate of virological fail-
ure compared to a less or equivalent weight (uHR =
0.39, 95 % CI: 0.17-0.89, P = 0.025. In addition, a base-
line one-Kilogram body weight difference: 41 kg to 42
kg and over was associated with 8 % reduced hazard
rate of virological failure (uHR = 0.92, 95 % CI: 0.86-
0.98, P = 0.008).
Table 1 Socio-demographic characteristics
Variable Total (N = 383)
Age in years
Below or equals 30 169 (44.1)











One partner is dead 24 (6.3)
Occupation
Formal employment 79 (20.6)
Self-employment 167 (43.6)












Ma’ di 14 (3.7)
Luo 79 (20.6)
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We dichotomized the baseline CD4 cell count using
the median value of 250 cells/ul. Our analysis indicated
that, HIV-infected adults with a baseline CD4 count
greater than 250.0 cells/ul significantly had reduced haz-
ard rate of virological failure compared to those that had
a baseline CD4 cell count less than 250.0 cells/ul (uHR
= 0.26, 95 % CI: 0.11-0.61, P = 0.002). Similarly, for every
1-additional CD4 cell count increase above the mini-
mum value of 41 cells/ul, the hazard rate of virological
failure significantly reduced by 1 % (uHR = 0.99, 95 %
CI: 0.99-1.0, P = 0.005).
The most recent CD4 cell count was dichotomized
using the median value of 362.0 cells/ul. Analysis
showed that HIV-infected adults with the most recent
CD4 cell count more than 362.0 cells/ul significantly
had reduced hazard rate of virological failure compared
to those with less or equal to 362.0 cells/ul (uHR =0.34,
95 % CI: 0.15-0.81, P = 0.015). Additionally, for every 1-
CD4 cell count increase above 35.0 cells/ul, the hazard
rate of virological failure significantly reduced (uHR =
0.99, 95 % CI: 0.99-1.00, P < 0.001).
HIV-positive adults with undisclosed HIV-serostatus
had higher incidence rate of virological failure compared
to those with disclosed HIV-serostatus. Disclosure of
HIV sero-status was associated with 82.0 % lower hazard
rate of virological failure (uHR = 0.18, 95 % CI: 0.08-
0.37, P < 0.001).
Multivariable analysis of factors associated with
virological failure among HIV-positive adults on first-line
ART in Northwestern Uganda
After adjusted analysis, three factors (baseline body weight
in kilograms, most recent CD4 cell count after ART initi-
ation and HIV-serostatus disclosure) were significantly as-
sociated virological failure (Table 2). HIV-positive adults
with a baseline body weight less or equal 56 kg had similar
hazard rates of virological failures compared to those that
had and more than 56 kg (Adjusted hazard ratio (aHR) =
1.14, 95%CI: 0.31-4.14, P = 0.845). But for every 1-kg body
weight increase above baseline body weight of 41- kg, the
adjusted hazard rate of virological failure significantly re-
duced (aHR = 0.86, 95 % CI: 0.76-0.96, P = 0.008).
HIV-positive adults with most recent CD4 cell count
(while on ART) increase of more than 362 cells/uL com-
pared to those with a less or equivalent increase had
over fivefold higher adjusted hazard rate of virological
failure (aHR = 5.02, 95 % CI: 1.11-22.72, P = 0.056). In
addition, every 1-CD4 cell count increase above 35.0
cells/ul led to a 1.0 % reduction in the adjusted hazard
rate of virological failure (aHR = 0.99, 95 % CI: 0.98-0.99,
P < 0.001).
Compared to none disclosure of HIV-serostatus, disclos-
ure of HIV-serostatus (to a spouse, friend, relative or friend)
was associated with 85.0 % reduction in adjusted hazard
rate of virological failure (aHR = 0.15, 95 % CI: 0.06-0.33, P
< 0.001). Actually, HIV-positive adults with disclosed HIV-
serostatus had superior survival of virological failure than
those with undisclosed HIV-serostatus (Fig. 2). This differ-
ence was highly statistically significant (Log-rank test, Chi-
squared test value =27.3, 1° of freedom, P < 0.0001).
Similar hazard rates of virological failure (Table 2)
were observed among female HIV-infected adults com-
pared to males (aHR = 0.45, 95 % CI: 0.19-1.03, P =
0.059), among adults in baseline WHO clinical stage III
/IV compared to WHO clinical stages I/II (aHR = 0.60,
95 % CI: 0.08-4.80, P = 0.632), between those with 1-
CD4 cell count higher at ART initiation (aHR = 1.01, 95
% CI: 1.00-1.01, P = 0.133) and, between those with base-
line CD4 cell counts less or equal to 250.0 cells/uL com-
pared to those with baseline CD4 count more than 250.0
cells/uL (aHR = 0.32, 95 % CI: 0.08-1.20, P = 0.091).
Discussion
Following revisions in the Uganda ART guidelines, this
was the first study to investigate the incidence and fac-
tors associated with virological failure among HIV-
positive adults at Arua Teaching and Regional Referral
Hospital HIV clinic in Northwestern Uganda.
The cumulative incidence of virological failure was
7.3 % compared to 1.3 % among Ethiopian HIV-positive
adults that received care at private health facilities [4].
The incidence rate of virological failure was 58 per 1000
person-years much higher than 27.9 per 1000 person-
years among HIV-infected adults in Thailand [5]. In
South Africa, a 19 % cumulative incidence of virological
failure was reported in a study that investigated the rela-
tionship between virological failure and drug refill visits.
However, the South African study defined virological
failure by lower plasma viral load of at least 50 copies/
ml after at least three months of ART [6]. Unlike the
present study, the duration of ART was shorter to en-
sure significant viral load suppression and the plasma
viral load threshold was low.
Our results indicated that HIV-serostatus disclosure
reduced virological failure. This was expected. It is com-
mon acceptance that disclosure of HIV serostatus reduce
HIV transmission risk and positively influence ART
adherence. In Tanzania, disclosure of HIV serostatus led
to provision of emotional and financial support to HIV-
infected adults and improved adherence to ART [7]. Al-
though HIV serostatus disclosure is very important, it
must be well-handled to prevent loss of support from
friends and family members [8]. Indeed in some quar-
ters, HIV serostatus-related discrimination and divorce
was reported [7].
The relationship between virologic failure and HIV
serostatus disclosure is somewhat limiting. One study in
Tanzania on HIV serostatus disclosure in a treatment
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Table 2 Incidence rate per 1000 person years, unadjusted and adjusted hazard ratios of association between patient and clinical










P-value aHR (95 % CI)
Adjusted for all variables
with P < 5 % at unadjusted
level & WHO clinical stage
P-value
Age in years
Below 30 169 (44.1) 12 57.2 (32.5-100.7) 1
Above 30 214 (55.9) 16 58.7 (35.9-95.7) 0.98 (0.46-2.08) 0.947
Residence
Rural 294 (76.8) 25 67.3 (45.5-99.7) 1
Urban 89 (23.2) 3 26.9 (8.7-83.5) 0.40 (0.12-1.33) 0.134
Marital status
Single 54 (14.1) 6 103.2 (46.4-229.8) 1
Married 234 (61.1) 15 50.6 (30.5-83.8) 0.36 (0.14-0.95) 0.05
Separated 71 (18.5) 6 62.8 (28.2-139.8) 0.43 (0.13-1.35) 0.148
One partner is dead 24 (6.3) 1 31.0 (4.4-219.8) 0.20 (0.02-1.67) 0.136
Occupation
Formal employment 79 (20.6) 7 72.1 (34.4-151.3) 1
Self-employment 167 (43.6) 11 52.0 (28.8-93.9) 0.64 (0.25-1.67) 0.362
Not employed 137 (35.8) 10 57.4 (30.9-106.8) 0.73 (0.28-1.91) 0.519
Educational level
None 41 (10.7) 4 76.1 (28.6-202.8) 1
Primary 95 (24.8) 4 32.3 (12.1-86.0) 0.40 (0.10-1.61) 0.199
Secondary 154 (40.2) 12 63.1 (35.9-111.2) 0.86 (0.28-2.67) 0.795
Tertiary 93 (24.3) 8 68.9 (34.5-137.8) 0.96 (0.29-3.19) 0.946
Religion
Catholic 203 (53.0) 14 53.9 (31.9-91.0) 1
Moslem 46 (12.0) 2 38.4 (9.6-153.4) 0.78 (0.18-3.46) 0.749
Anglican 134 (35.0) 12 70.3 (39.9-123.7) 1.28 (0.59-2.77) 0.529
Tribe
Lugbara 290 (75.7) 17 47.3 (29.4-76.1) 1 1
Ma’ di 14 (3.7) 1 57.7 (8.1-409.8) 1.20 (0.16-9.04) 0.860
Luo 79 (20.6) 10 94.2 (50.7-175.2) 1.82 (0.83-3.94) 0.134
Sex
Male 145 (37.9) 14 (9.7) 82.0 (48.2-138.4) 1 1
Female 238 (62.1) 14 (5.9) 44.9 (26.6-75.8) 0.45 (0.21-0.95) 0.035 0.45 (0.19-1.03) 0.059
Baseline WHO staging 1 1
I/II 359 (93.7) 21 (5.8) 59.6 (40.9-86.9) 0.60 (0.08-4.40) 0.612 0.60 (0.08-4.80) 0.632
III/IV 24 (6.3) 7 (29.2) 33.9 (4.8-240.4)
Baseline weight/Kgs
Less or equals 56 Kgs 194 (50.7) 20 (10.3) 82.0 (52.9-127.1) 1 1
More than 56 Kgs 189 (49.4) 8 (4.2) 33.5 (16.8-67.0) 0.39 (0.17-0.89) 0.025 1.14 (0.31-4.14) 0.845
1-kg increase 0.92 (0.86-0.98) 0.008 0.86 (0.76-0.96) 0.008
Baseline CD4 cells/uL
Less or equals 250 cells/uL 192 (50.1) 21 (10.9) 92.3 (60.2-141.6) 1 1
More than 250 cells/uL 191 (49.9) 7 (3.7) 27.4 (13.1-57.6) 0.26 (0.11-0.61) 0.002 0.32 (0.08-1.20) 0.091
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cascade found no evidence in support of HIV serostatus
disclosure and undetectable viral loads. Interestingly,
nondisclosure of HIV serostatus led to lost linkage to
HIV chronic care [9]. Unlike our findings, a study in
Ethiopia reported reduction in the incidence of viro-
logical failure among HIV-infected adults with undis-
closed HIV serostatus [4]. This was very surprising
because HIV serostatus disclosure is known to enhance
psychosocial support, to boost ART adherence and ul-
timately treatment outcomes. With disregard to these
contradictions, current psychosocial support approaches
must help HIV-positive persons to disclose their HIV-
serostatus to meaningful gain its benefits like family sup-
port in long term chronic care. Mostly, psychosocial
support is key in ART adherence support, stigma and
discrimination reduction and, retention in HIV care.
Our study found an extra 1-CD4 cell count rise above
35 cells/mm3 after ART initiation reduced the hazard rate
of virological failure. This result needs cautious interpret-
ation. Published reports indicate rising CD4 counts are
undermined by very low positive predictive values in de-
tecting suppressed viral loads and vice-versa [10]. Sec-
ondly, CD4 cell counts are ineffective in predicting early
virological failure than viral load tests [1, 3]. Also, CD4 cell
counts strongly correlate with virological failure at individ-
ual level than at group level [11]. In Thailand, recent CD4
cell count increase of more than 50 cells/mm3 was associ-
ated with immunological failure but not virological failure
among ART-naïve HIV-infected adults on Protease Inhibi-
tor containing regimen [5].
In South Africa, no significant association was found
between CD4 cell count and virological failure in a study
that examined the association between virological failure
and drug refill visits [6]. Current recommendations pro-
mote viral load monitoring but, it is expensive and not
easily afforded by most health systems in Africa [1, 3]. In
Uganda, coverage of viral load testing is still very low in
both urban and rural settings but, efforts in increasing
the coverage across the country through training of
health workers in sample collection is evident. Our study
thus re-emphasis the contribution of CD4 cell counts in
predicting virological failure before overt clinical failure
in resource limited settings. In the absence of viral load
tests, CD4 cell counts may be useful in clinical patient
management.
We found a 1-kg baseline body weight above 41 kg re-
duced the hazard rate of virological failure. Contrary to our
findings, two studies revealed an increased risk of
Table 2 Incidence rate per 1000 person years, unadjusted and adjusted hazard ratios of association between patient and clinical
factors with virological failure (Continued)
1-CD4 cell increase 0.99 (0.99-0.10) 0.005 1.01 (1.00-1.01) 0.133
Recent CD4 cells/uL
Less or equals 362 cells/uL 194 (50.7) 21 (10.8) 84.9 (55.3-130.1) 1 1
More than 362 cells/uL 189 (49.3) 7 (3.7) 29.8 (14.2-62.4) 0.36 (0.15-0.85) 0.021 5.02 (1.11-22.72) 0.056
1-CD4 cell increase/uL 0.99 (0.99-1.00) <0.001 0.99 (0.98-0.99) <0.001
HIV sero-status disclosure
No 68 (17.8) 14 (20.6) 177.9 (105.4-300.4) 1 1
Yes 315 (82.3) 14 (44.4) 34.7 (20.5-58.5) 0.18 (0.08-0.37) <0.001 0.15 (0.06-0.33) <0.001
Note
-Percentages calculated as row percentages (n/N)
-Level of significance was 5 %
-Bolded P-values are significant at 5 %
-uHR Unadjusted Hazard Ratio, aHR Adjusted Hazard Ratio, CI Confidence interval, WHO World Health Organization, CD4 Cluster of Cell Differentiation-4
Fig. 2 Kaplan-Meier survival probabilities between HIV-positive adults with and without sero-status disclosure, Arua Teaching and Regional Refer-
ral Hospital, Northwestern Uganda
Izudi et al. BMC Infectious Diseases  (2016) 16:614 Page 6 of 8
virological failure with higher baseline body weight [12, 13].
Unlike this study, these evidence was among patients on
ART regimen containing Protease Inhibitors. In Ethiopia, a
baseline body weight less than 50 kg was associated with re-
duced hazard rate of virological failure [4]. This study and
the Ethiopian study confirmed that HIV-positive adults
with baseline body weight less than 50 kg have increased
hazard rate of virological failure. However, the Ethiopian
study was conducted in a private healthcare setting whereas
the present study was in public healthcare setting. Health-
care workers in both private and public health settings
must routinely conduct nutritional assessments (weight,
height and mid-upper arm circumference) at baseline and
during follow-up visits to improve patient clinical care.
Studies in Malawi [14] and Tanzania [15] underscored
the importance of nutritional assessment in ART care. In
particular, the study in Malawi found an increase in body
mass index (BMI) (measured by weight/kg per height/m
squared) by less than 0.5 kg/m2 and MUAC by less than
0.5 cm after two weeks of ART strongly associated with
high risk of death among HIV-positive adults [14]. The
risk of death associated with reduced BMI while on ART
was highest within the first three months [14]. In
Tanzania, loss of any body weight was associated with
death among HIV-positive adults on ART [15]. The loss
of body weight persisted to predict high risk of death up
to 1-year of ART [15]. The past studies [14, 15] and
present study highlighted the importance of nutritional
assessment, counseling and support in HIV care, treat-
ment and support services.
We found no association between gender, age, baseline
CD4 cell count and WHO clinical staging with viro-
logical failure. This is consistent with previous study in
resource limited setting [11].
Conclusion
This study highlighted the magnitude and predictors of
virological failure among HIV-positive adults following
the implementation of the revised ART guidelines in
Uganda at Arua HIV Clinic, Northwestern Uganda. The
incidence rate of virological failure was low at 58 per
1000 person-years. Rising CD4 cell counts after ART ini-
tiation (above 35 cells/ul), HIV-serostatus disclosure and
baseline body weight above 41 kg were associated with
reduced hazard rate of virological failure.
Recommendation
In resource poor settings (where routine viral load tests
are not feasible), rising CD4 cell counts while on ART
may still be an alternative option for monitoring patient
response to ART and predicting clinical outcomes. Sec-
ondly, HIV-positive persons aged 12 years and above
must be supported in HIV-serostatus disclosure. This
will enable them derive the benefits of psychosocial
support. Finally, good nutritional status is critical for
successful ART outcomes. Particularly, deliberate efforts
in nutritional assessment, counseling and support are ur-
gently needed in HIV care.
Limitations
Like other studies, our study had flaws. First, the use of
secondary data limited the number of variables that
would be essential in making conclusions on virological
failure. Secondly, there was lack of qualitative data on
patient experiences to explain the observed outcomes.
However, these limitations do not override the results as
efforts were taken to explicitly explain and relate the
findings to previous published studies. Importantly, this
study was the first in Uganda to examine virological fail-
ure after the Ministry of Health adopted the WHO ART
guidelines with a policy shift to TDF/3TC/EFV as the
preferred first-line ART option. We have therefore set
an important benchmark for policy makers, prospective
researchers and program managers in improving clinical
care of HIV-infected persons in Uganda.
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